↓ Skip to main content

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, December 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
1 news outlet
twitter
10 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
272 Dimensions

Readers on

mendeley
358 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, December 2017
DOI 10.1186/s13195-017-0318-y
Pubmed ID
Authors

Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura

Abstract

Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer's disease (AD). In this randomized, double-blind, placebo-controlled phase III study, we investigated gantenerumab over 2 years. Patients were randomized to gantenerumab 105 mg or 225 mg or placebo every 4 weeks by subcutaneous injection. The primary endpoint was the change from baseline to week 104 in Clinical Dementia Rating Sum of Boxes (CDR-SB) score. We evaluated treatment effects on cerebrospinal fluid biomarkers (all patients) and amyloid positron emission tomography (substudy). A futility analysis was performed once 50% of patients completed 2 years of treatment. Safety was assessed in patients who received at least one dose. Of the 3089 patients screened, 797 were randomized. The study was halted early for futility; dosing was discontinued; and the study was unblinded. No differences between groups in the primary (least squares mean [95% CI] CDR-SB change from baseline 1.60 [1.28, 1.91], 1.69 [1.37, 2.01], and 1.73 [1.42, 2.04] for placebo, gantenerumab 105 mg, and gantenerumab 225 mg, respectively) or secondary clinical endpoints were observed. The incidence of generally asymptomatic amyloid-related imaging abnormalities increased in a dose- and APOE ε4 genotype-dependent manner. Exploratory analyses suggested a dose-dependent drug effect on clinical and biomarker endpoints. The study was stopped early for futility, but dose-dependent effects observed in exploratory analyses on select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve clinical efficacy. ClinicalTrials.gov, NCT01224106 . Registered on October 14, 2010.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 358 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 358 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 57 16%
Student > Master 45 13%
Student > Ph. D. Student 40 11%
Researcher 32 9%
Other 25 7%
Other 44 12%
Unknown 115 32%
Readers by discipline Count As %
Neuroscience 48 13%
Medicine and Dentistry 45 13%
Biochemistry, Genetics and Molecular Biology 41 11%
Agricultural and Biological Sciences 23 6%
Pharmacology, Toxicology and Pharmaceutical Science 19 5%
Other 50 14%
Unknown 132 37%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2021.
All research outputs
#1,455,389
of 22,121,923 outputs
Outputs from Alzheimer's Research & Therapy
#221
of 1,159 outputs
Outputs of similar age
#41,181
of 448,026 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#15
of 95 outputs
Altmetric has tracked 22,121,923 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,159 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,026 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.